DURECT Corp (DRRX) – Strategy, SWOT and Corporate Finance Report
- Pages: 53
- Published: June 2023
- Report Code: MLME305FSA
DURECT Corp (DRRX) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company
Key Highlights
DURECT Corp (Durect) is a biopharmaceutical company that focuses on the research and development of new chemical entities for the treatment of acute organ injury and chronic liver diseases based on its endogenous epigenetic regulator program. The company’s major product pipeline comprises DUR-928, indicated for the treatment of alcoholic hepatitis and nonalcoholic steatohepatitis (NASH); Posimir, indicated to treat post-operative pain; and Oradur, indicated for chronic pain and attention deficit hyperactivity disorders. Durect also manufactures and sells osmotic pumps for laboratory research; and offers standard and custom biodegradable polymers and excipients for customers in pharmaceutical and medical device industry. The company operates in the US, Europe, Japan and other countries. Durect is headquartered in Cupertino, California, the US.
Scope
• Detailed information on DURECT Corp required for business and competitor intelligence needs
• A study of the major internal and external factors affecting DURECT Corp in the form of a SWOT analysis
• An in-depth view of the business model of DURECT Corp including a breakdown and examination of key business segments
• News about DURECT Corp, such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to buy
• Gain understanding of DURECT Corp and the factors that influence its strategies.• Track strategic initiatives of the company and latest corporate news and actions.
• Assess DURECT Corp as a prospective partner, vendor or supplier.
• Support sales activities by understanding your customers' businesses better.
• Stay up to date on DURECT Corps business structure, strategy and prospects.
Note: Some sections may be missing if data is unavailable for the company.
Companies mentioned
AstraZeneca Plc
Medtronic Plc
Mallinckrodt Plc
Eli Lilly and Co
Immune Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc
Pacira BioSciences Inc
Knoll Inc
AbbVie Inc
Purdue Pharma LP
Acorda Therapeutics Inc
Avadel Pharmaceuticals Plc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.